TECX Tectonic Therapeutic Inc.

Price (delayed)

$20.08

Market cap

$400.56M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.63

Enterprise value

$169.81M

?
Relative Growth: Rel. Growth: 2
Relative Strength: Rel. Strength: 30
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 4

AVROBIO, Inc. is a leading, Phase 2 gene therapy company focused on the development of its investigational gene therapy, AVR-RD-01, in Fabry disease, as well as additional gene therapy programs ...

Highlights
TECX's debt is down by 11% since the previous quarter
Tectonic Therapeutic's equity has decreased by 14% YoY but it has increased by 2.4% from the previous quarter
The EPS has dropped by 72% year-on-year
Tectonic Therapeutic's quick ratio has decreased by 33% YoY and by 12% from the previous quarter

Key stats

What are the main financial stats of TECX

TECX stock price

How has the Tectonic Therapeutic stock price performed over time
Intraday
-4.29%
1 week
-8.6%
1 month
-2.76%
1 year
9.25%
YTD
-3.74%
QTD
-13.78%

Financial performance

How have Tectonic Therapeutic's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$96.49M
Net income
-$88.1M
Gross margin
N/A
Net margin
N/A
TECX's net income is down by 31% year-on-year and by 2.7% since the previous quarter
TECX's operating income is down by 26% year-on-year

Price vs fundamentals

How does TECX's price correlate with its fundamentals

Growth

What is Tectonic Therapeutic's growth rate over time

Valuation

What is Tectonic Therapeutic stock price valuation
P/E
N/A
P/B
1.71
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has dropped by 72% year-on-year
TECX's price to book (P/B) is 38% more than its 5-year quarterly average of 1.3 but 19% less than its last 4 quarters average of 2.2
Tectonic Therapeutic's equity has decreased by 14% YoY but it has increased by 2.4% from the previous quarter

Efficiency

How efficient is Tectonic Therapeutic business performance
The ROIC has increased by 44% from the previous quarter
Tectonic Therapeutic's ROE has decreased by 39% YoY and by 7% from the previous quarter
The return on assets has declined by 37% year-on-year and by 6% since the previous quarter

Dividends

What is TECX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TECX.

Financial health

How did Tectonic Therapeutic financials performed over time
The total liabilities has soared by 53% YoY and by 10% QoQ
Tectonic Therapeutic's quick ratio has decreased by 33% YoY and by 12% from the previous quarter
TECX's debt is 98% smaller than its equity
Tectonic Therapeutic's equity has decreased by 14% YoY but it has increased by 2.4% from the previous quarter
TECX's debt is down by 11% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.